Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Controlled-Release, a once-daily oral tablet for the treatment of Prader-Willi Syndrome, which is being evaluated in an ongoing Phase III clinical development program. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is based in Redwood City, California.

Soleno Therapeutics, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

REDWOOD CITY, CALIF., AUG. 06, 2025 (GLOBE NEWSWIRE) -- SOLENO THERAPEUTICS, INC. (SOLENO) (NASDAQ: SLNO), A BIOPHARMACEUTICAL COMPANY DEVELOPING NOVEL THERAPEUTICS FOR THE TREATMENT OF RARE DISEASES, TODAY PROVIDED AN UPDATE ON THE U.S. LAUNCH OF VYKATTM XR AND REPORTED FINANCIAL RESULTS FOR THE SECOND QUARTER ENDED JUNE 30, 2025.

SOLENO THERAPEUTICS PROVIDES UPDATE ON U.S. LAUNCH OF VYKAT(TM) XR AND REPORTS SECOND QUARTER 2025 FINANCIAL RESULTS

REDWOOD CITY, CALIF., JULY 10, 2025 (GLOBE NEWSWIRE) -- SOLENO THERAPEUTICS, INC. (SOLENO)(NASDAQ: SLNO), A BIOPHARMACEUTICAL COMPANY DEVELOPING NOVEL THERAPEUTICS FOR THE TREATMENT OF RARE DISEASES, ANNOUNCED TODAY THAT IT HAS PRICED ITS PREVIOUSLY ANNOUNCED UNDERWRITTEN PUBLIC OFFERING OF 2,352,941 SHARES OF ITS COMMON STOCK AT A PRICE TO THE PUBLIC OF$85.00PER SHARE. ALL OF THE SHARES ARE BEING SOLD BY SOLENO. IN ADDITION, SOLENO HAS GRANTED THE UNDERWRITERS A 30-DAY OPTION TO PURCHASE UP TO AN ADDITIONAL 352,941 SHARES OF ITS COMMON STOCK AT THE PUBLIC OFFERING PRICE. THE GROSS PROCEEDS FROM THE OFFERING ARE EXPECTED TO BE APPROXIMATELY$200 MILLIONBEFORE DEDUCTING UNDERWRITING DISCOUNTS AND COMMISSIONS AND OTHER OFFERING EXPENSES, ASSUMING NO EXERCISE OF THE UNDERWRITERS' OPTION TO PURCHASE ADDITIONAL SHARES.THE OFFERING IS EXPECTED TO CLOSE ON OR ABOUTJULY 11, 2025, SUBJECT TO SATISFACTION OF CUSTOMARY CLOSING CONDITIONS.

SOLENO THERAPEUTICS ANNOUNCES PRICING OF $200 MILLION PUBLIC OFFERING OF COMMON STOCK

REDWOOD CITY, CALIF., JULY 10, 2025 (GLOBE NEWSWIRE) -- SOLENO THERAPEUTICS, INC.(SOLENO) (NASDAQ:SLNO), A BIOPHARMACEUTICAL COMPANY DEVELOPING NOVEL THERAPEUTICS FOR THE TREATMENT OF RARE DISEASES, ANNOUNCED TODAY THAT IT INTENDS TO OFFER AND SELL $200 MILLION OF SHARES OF ITS COMMON STOCK IN AN UNDERWRITTEN PUBLIC OFFERING. IN ADDITION, SOLENO INTENDS TO GRANT THE UNDERWRITERS A 30-DAY OPTION TO PURCHASE UP TO AN ADDITIONAL $30 MILLION OF SHARES OF COMMON STOCK. THE PROPOSED PUBLIC OFFERING IS SUBJECT TO MARKET CONDITIONS, AND THERE CAN BE NO ASSURANCE AS TO WHETHER OR WHEN THE OFFERING MAY BE COMPLETED, OR AS TO THE ACTUAL SIZE OR TERMS OF THE OFFERING.

SOLENO THERAPEUTICS ANNOUNCES PROPOSED $200 MILLION PUBLIC OFFERING OF COMMON STOCK

REDWOOD CITY, CALIF., JULY 10, 2025 (GLOBE NEWSWIRE) -- SOLENO THERAPEUTICS, INC.(SOLENO) (NASDAQ: SLNO), A BIOPHARMACEUTICAL COMPANY DEVELOPING NOVEL THERAPEUTICS FOR THE TREATMENT OF RARE DISEASES, ANNOUNCED TODAY CERTAIN PRELIMINARY UNAUDITED FINANCIAL AND OPERATIONAL RESULTS FOR THE THREE MONTHS ENDED JUNE 30, 2025:

SOLENO THERAPEUTICS ANNOUNCES PRELIMINARY FINANCIAL AND OPERATIONAL RESULTS FOR THE SECOND QUARTER ENDED JUNE 30, 2025

CONFERENCE IS THE FIRST-EVER INTERNATIONAL MEETING JOINTLY HOSTED BY THE PRADER-WILLI SYNDROME ASSOCIATION | USA, THE FOUNDATION FOR PRADER-WILLI RESEARCH, AND THE INTERNATIONAL PRADER-WILLI SYNDROME ORGANISATION CONFERENCE IS THE FIRST-EVER INTERNATIONAL MEETING JOINTLY HOSTED BY THE PRADER-WILLI SYNDROME ASSOCIATION | USA, THE FOUNDATION FOR PRADER-WILLI RESEARCH, AND THE INTERNATIONAL PRADER-WILLI SYNDROME ORGANISATION

SOLENO THERAPEUTICS ANNOUNCES MULTIPLE PRESENTATIONS AT THE 2025 UNITED IN HOPE: INTERNATIONAL PRADER-WILLI SYNDROME CONFERENCE

REDWOOD CITY, CALIF., MAY 22, 2025 (GLOBE NEWSWIRE) -- SOLENO THERAPEUTICS, INC. (SOLENO) (NASDAQ: SLNO), A BIOPHARMACEUTICAL COMPANY DEVELOPING NOVEL THERAPEUTICS FOR THE TREATMENT OF RARE DISEASES, TODAY ANNOUNCED THAT SOLENO'S MARKETING AUTHORIZATION APPLICATION (MAA) SEEKING REGULATORY APPROVAL OF DIAZOXIDE CHOLINE PROLONGED-RELEASE TABLETS (PREVIOUSLY REFERRED TO AS DCCR) FOR THE TREATMENT OF ADULTS AND CHILDREN FOUR YEARS AND OLDER WITH PRADER-WILLI SYNDROME (PWS) WHO HAVE HYPERPHAGIA HAD BEEN VALIDATED BY THE EUROPEAN MEDICINES AGENCY (EMA).

SOLENO THERAPEUTICS ANNOUNCES SUBMISSION AND EMA VALIDATION OF MARKETING AUTHORIZATION APPLICATION FOR DIAZOXIDE CHOLINE PROLONGED-RELEASE TABLETS FOR THE TREATMENT OF HYPERPHAGIA IN PATIENTS WITH PRADER-WILLI SYNDROME

REDWOOD CITY, CALIF., MAY 20, 2025 (GLOBE NEWSWIRE) -- SOLENO THERAPEUTICS, INC. (NASDAQ: SLNO), A BIOPHARMACEUTICAL COMPANY DEVELOPING NOVEL THERAPEUTICS FOR THE TREATMENT OF RARE DISEASES, TODAY ANNOUNCED DATA PRESENTED FROM ITS CLINICAL DEVELOPMENT PROGRAM OF VYKATXR (DIAZOXIDE CHOLINE) EXTENDED-RELEASE TABLETS, PREVIOUSLY REFERRED TO AS DCCR, AT THE PEDIATRIC ENDOCRINE SOCIETY (PES) ANNUAL MEETING 2025, WHICH WAS HELD MAY 15-18 IN NATIONAL HARBOR, MARYLAND, USA. THE PRESENTATION SHOWED THAT RESUMPTION OF VYKAT XR TREATMENT IN PARTICIPANTS WITH PWS FOLLOWING A 16-WEEK RANDOMIZED WITHDRAWAL WAS ASSOCIATED WITH SIGNIFICANT IMPROVEMENTS IN BOTH HYPERPHAGIA AND BEHAVIORAL SYMPTOMS.

SOLENO THERAPEUTICS ANNOUNCES DATA PRESENTATION SHOWING THAT RESUMPTION OF TREATMENT WITH VYKAT(TM) XR AFTER A RANDOMIZED WITHDRAWAL PERIOD WAS ASSOCIATED WITH SIGNIFICANT IMPROVEMENTS IN HYPERPHAGIA AND BEHAVIORAL SYMPTOMS IN PARTICIPANTS WITH PRADER-WILLI SYNDROME

REDWOOD CITY, CALIF., MAY 07, 2025 (GLOBE NEWSWIRE) -- SOLENO THERAPEUTICS, INC. (SOLENO) (NASDAQ: SLNO), A BIOPHARMACEUTICAL COMPANY DEVELOPING NOVEL THERAPEUTICS FOR THE TREATMENT OF RARE DISEASES, TODAY PROVIDED AN UPDATE ON THE U.S. LAUNCH OF VYKATTM XR AND REPORTED FINANCIAL RESULTS FOR THE FIRST QUARTER ENDED MARCH 31, 2025.

SOLENO THERAPEUTICS PROVIDES UPDATE ON U.S. LAUNCH OF VYKAT(TM) XR AND REPORTS FIRST QUARTER 2025 FINANCIAL RESULTS

REDWOOD CITY, CALIF., APRIL 23, 2025 (GLOBE NEWSWIRE) -- SOLENO THERAPEUTICS, INC. (SOLENO) (NASDAQ: SLNO), A BIOPHARMACEUTICAL COMPANY DEVELOPING NOVEL THERAPEUTICS FOR THE TREATMENT OF RARE DISEASES, TODAY ANNOUNCED THAT IT WILL REPORT ITS FIRST QUARTER 2025 FINANCIAL RESULTS, AS WELL AS OPERATIONAL HIGHLIGHTS, AFTER THE CLOSE OF THE U.S. FINANCIAL MARKETS ON WEDNESDAY, MAY 7, 2025. THE COMPANY WILL HOST A CONFERENCE CALL AND WEBCAST AT 4:30 PM EASTERN TIME TO DISCUSS THE RESULTS AND PROVIDE AN UPDATE ON BUSINESS OPERATIONS.

SOLENO THERAPEUTICS TO REPORT FIRST QUARTER 2025 FINANCIAL RESULTS AND HOST INAUGURAL QUARTERLY CONFERENCE CALL ON MAY 7, 2025, AT 4:30 PM ET

REDWOOD CITY, CALIF., APRIL 14, 2025 (GLOBE NEWSWIRE) -- SOLENO THERAPEUTICS, INC. (SOLENO) (NASDAQ: SLNO), A BIOPHARMACEUTICAL COMPANY DEVELOPING NOVEL THERAPEUTICS FOR THE TREATMENT OF RARE DISEASES, TODAY ANNOUNCED THE U.S. COMMERCIAL AVAILABILITY OF VYKAT XR (DIAZOXIDE CHOLINE) EXTENDED-RELEASE TABLETS, THE COMPANY'S TREATMENT FOR HYPERPHAGIA IN PATIENTS FOUR YEARS OF AGE AND OLDER WITH PRADER-WILLI SYNDROME (PWS), WHICH WAS APPROVED BY THE U.S. FOOD AND DRUG ADMINISTRATION (FDA) ON MARCH 26, 2025.

Soleno Therapeutics, Inc.

SLNO

Price

Financials Overview

Financial Reports

No items found.

Press Releases

Soleno Therapeutics, Inc.

SLNO.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

SLNO